U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049328) titled 'HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata' on June 04.
Brief Summary: This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
Study Start Date: Aug. 16
Study Type: INTERVENTIONAL
Condition:
Alopecia Areata(AA)
Intervention:
DRUG: HCW9302, an IL-2 fusion protein
Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: HCW Biologics
Disclaimer: Curated by HT Syndication....